This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción ELN
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de Elanix Biotechnologies AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.053 |
| 52 Week High | €0.20 |
| 52 Week Low | €0.0005 |
| Beta | 0 |
| 1 Month Change | 6.00% |
| 3 Month Change | -37.65% |
| 1 Year Change | -64.67% |
| 3 Year Change | -94.75% |
| 5 Year Change | -98.20% |
| Change since IPO | -100.00% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| ELN | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -11.7% | -5.1% | -2.0% |
| 1Y | -64.7% | -21.1% | -0.3% |
Rentabilidad vs. Industria: ELN underperformed the German Biotechs industry which returned -5.5% over the past year.
Rentabilidad vs. Mercado: ELN underperformed the German Market which returned 2.4% over the past year.
Volatilidad de los precios
| ELN volatility | |
|---|---|
| ELN Average Weekly Movement | 3,131.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: ELN's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: ELN's weekly volatility has increased from 1714% to 3131% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | n/a | Lee-Ann Laurent-Applegate | www.elanixbiotechnologies.ch |
Resumen de fundamentos de Elanix Biotechnologies AG
| Estadísticas fundamentales de ELN | |
|---|---|
| Capitalización bursátil | €428.29k |
| Beneficios(TTM) | -€4.46m |
| Ingresos (TTM) | €280.19k |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está ELN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ELN | |
|---|---|
| Ingresos | €280.19k |
| Coste de los ingresos | €348.59k |
| Beneficio bruto | -€68.39k |
| Otros gastos | €4.39m |
| Beneficios | -€4.46m |
Últimos beneficios comunicados
Jun 30, 2018
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0.0% |
¿Cómo se ha desempeñado ELN a largo plazo?
Ver rendimiento histórico y comparativa